Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI audit states the “WARNING: ANAPHYLAXIS” claim is supported by the supplied XOLAIR label sections (Boxed Warning, 5.1, 6.2, and 2.6). No contradictions or omissions are asserted against the provided label excerpts.
Category Scores
Accurate Statements
The anaphylaxis warning claim is directly supported by the FDA labeling (Boxed Warning, section 5.1, section 6.2, and section 2.6).
Supported by the provided excerpts: BOXED WARNING (Anaphylaxis); 5.1 Anaphylaxis; 6.2 Postmarketing Experience — Anaphylaxis; 2.6 Administration Overview — Selection of Patients for Self-Administration.
Boxed warning relevance: anaphylaxis with bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue; can occur as early as after the first dose and beyond 1 year; initiate in a healthcare setting and observe; ready to manage life-threatening reactions; inform patients to seek immediate care; includes criteria for self-administration selection.
All included in the provided boxed warning text and supported by 5.1 and 2.6 excerpts as referenced.
Precautions relevance: reported signs/symptoms and timing (including first dose and beyond one year), frequency estimates, patient education/seek care, and discontinuation in severe hypersensitivity reactions.
Supported by 5.1 Anaphylaxis excerpt, including frequency (e.g., 3 of 3507; and postmarketing frequency language) and discontinuation statement.
Postmarketing experience relevance: diagnostic criteria, signs/symptoms, estimated frequency, timing of onset, hospitalization rate, and recurrence on rechallenge.
Supported by 6.2 Postmarketing Experience — Anaphylaxis excerpt (diagnostic criteria, estimated frequency at least 0.2%, timing distribution, 15% hospitalization, rechallenge recurrence).
Self-administration mitigation relevance: patient selection criteria to mitigate anaphylaxis risk (e.g., no prior history of anaphylaxis to relevant agents and ability to recognize and treat anaphylaxis).
Supported by 2.6 Administration Overview — Selection of Patients for Self-Administration (criteria listed 1a/1b, 3, 4, and 5).
Final verdict: The anaphylaxis warning claim is consistent with and supported by FDA-approved labeling content as cited (Boxed Warning, 5.1, 6.2, and 2.6).
Consistent with the provided label excerpts.
Unsupported Statements
Contradictions
Important Omissions
The auditor result notes contraindications were not evaluated, but this specific evaluation prompt is for the ‘WARNING: ANAPHYLAXIS’ claim. No contraindication-related claim was made by the AI audit that would require contraindications label alignment.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The AI audit report is an evaluative statement about label support for the anaphylaxis warning; it does not introduce new dosing, contraindication, or management instructions beyond what the label excerpts support.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor: The report mentions contraindications were not evaluated, though the claim category assessed is anaphylaxis warning content.
Suggested Improvement
If contraindications are not part of the evaluated claim set, omit the contraindications review status to avoid implying a gap in the core warning assessment.